TG Therapeutics Inc. (TGTX) Stock Rating Reaffirmed by FBR & Co
TG Therapeutics Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by analysts at FBR & Co in a note issued to investors on Monday.
A number of other analysts have also commented on TGTX. Brean Capital reiterated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, May 31st. SunTrust Banks Inc. assumed coverage on TG Therapeutics in a report on Friday, May 27th. They set a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research lowered TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. Roth Capital reiterated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Thursday, June 9th. Finally, S&P Equity Research dropped their price target on TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $20.81.
Shares of TG Therapeutics (NASDAQ:TGTX) opened at 7.44 on Monday. The stock’s 50 day moving average price is $6.39 and its 200 day moving average price is $7.43. The firm’s market capitalization is $405.15 million. TG Therapeutics has a 12-month low of $5.41 and a 12-month high of $14.87.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. Equities research analysts expect that TG Therapeutics will post ($1.22) earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. Bridger Management LLC purchased a new stake in shares of TG Therapeutics during the first quarter valued at about $28,503,000. UBS Asset Management Americas Inc. raised its stake in shares of TG Therapeutics by 30.0% in the first quarter. UBS Asset Management Americas Inc. now owns 2,021,310 shares of the biopharmaceutical company’s stock valued at $17,223,000 after buying an additional 466,193 shares during the last quarter. Mariner Wealth Advisors LLC raised its stake in shares of TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 255 shares during the last quarter. State Street Corp raised its stake in shares of TG Therapeutics by 3.4% in the first quarter. State Street Corp now owns 1,181,038 shares of the biopharmaceutical company’s stock valued at $10,064,000 after buying an additional 39,117 shares during the last quarter. Finally, Opaleye Management Inc. raised its stake in shares of TG Therapeutics by 38.3% in the first quarter. Opaleye Management Inc. now owns 415,000 shares of the biopharmaceutical company’s stock valued at $3,536,000 after buying an additional 115,000 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.